BlackRock, Inc. 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
4,891,379 7.100% |
0 (Unchanged) |
Filing |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
4,891,379 7.100% |
2,804,816 (+134.42%) |
Filing |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
2,086,563 4.300% |
-1,534,570 (-42.38%) |
Filing |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
3,621,133 7.400% |
215,151 (+6.32%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
BlackRock Inc. BLK |
3,405,982 7.000% |
3,405,982 (New Position) |
Filing |